Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

The study proposed here intends to evaluate the safety and efficacy of escalating doses of autologous PMCC-COE-KMA CAR T-cells administered to patients with relapsed/refractory multiple myeloma that expresses the KMA. The PMCC-COE-KMA CAR T-cells will be produced using LV and administered to patients after lymphodepleting conditioning chemotherapy. Considering the poor prognosis of myeloma patients who have relapsed after ≥ 2 lines of therapy, combined with evidence of PMCC-COE-KMA CAR T-cell specificity, as well as the efficacy and manageable toxicity of PMCC-COE-KMA, investigators believe th

Trial Details

NCT ID
NCT07541391
Phase
PHASE1
Sponsor
Peter MacCallum Cancer Centre, Australia
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • PMCC-COE-KMA
Locations (sample)
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Patient has provided written informed consent using the KOALA Patient Information and Consent Form (PICF)
  • Age ≥ 18 years on the day of signing informed consent form
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2 (Appendix 2)
  • Life expectancy of ≥ 3 months, as assessed by the Investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →